IV Sildenafil for PPHN in Newborns Receiving iNO
Intravenous sildenafil is a reasonable adjunctive therapy for newborns with PPHN who remain refractory to inhaled nitric oxide, particularly when the oxygenation index exceeds 25 1.
Clinical Indication Algorithm
When to Consider IV Sildenafil:
Primary criteria (all must be met):
- Term or near-term infant (>34 weeks gestation)
- Confirmed PPHN on echocardiography with right-to-left shunting
- Already receiving iNO (typically 10-20 ppm)
- Oxygenation index (OI) >25 despite optimal ventilation
- Persistent hypoxemia after optimizing respiratory support
Before adding sildenafil, ensure:
- Lung recruitment strategies have been maximized (especially with parenchymal lung disease) 1
- Ventilator settings are optimized
- Cardiac function has been assessed (rule out left ventricular dysfunction)
- No underlying disorders like alveolar capillary dysplasia if failing to improve beyond 5 days 1
Evidence Quality and Strength
The 2015 AHA/ATS guidelines provide a Class IIa recommendation (Level of Evidence B) for sildenafil as adjunctive therapy in iNO-refractory PPHN 1. This means it is "reasonable" to use but not definitively proven superior.
Critical limitation: The most recent high-quality RCT (2021) showed that IV sildenafil added to iNO was NOT superior to placebo in reducing treatment failure rates or time on iNO 2. This study enrolled 59 infants with OI >15 to <60 already receiving iNO, and found no difference in primary outcomes. However, the study was underpowered and had high discontinuation rates.
Supporting evidence from resource-limited settings: A 2011 Cochrane review found sildenafil reduced mortality (RR 0.20) in settings without iNO availability 3. A 2009 dose-escalation trial showed improved oxygenation with higher IV sildenafil doses, though most patients were already on iNO 4.
Dosing Regimen
Based on the 2021 RCT protocol 2:
- Loading dose: 0.1 mg/kg IV over 30 minutes
- Maintenance: 0.03 mg/kg/hour continuous infusion
- Duration: Up to 14 days or until weaned from iNO
The 2009 trial used higher doses in escalation cohorts, with better responses at higher infusion rates 4, but the 2021 trial used the above conservative dosing.
Safety Considerations
Common adverse events (≥10% in 2021 trial) 2:
- Hypotension (most common - occurred in 28% with sildenafil)
- Hypokalemia
- Anemia
- Bradycardia
Critical monitoring:
- Blood pressure continuously (hypotension is dose-limiting)
- Electrolytes (especially potassium)
- Cardiac output/function
- Avoid in infants dependent on right-to-left shunting
Alternative Considerations
If sildenafil is being considered, also evaluate:
Inhaled prostacyclin analogs: Class IIb recommendation for iNO-refractory PPHN with OI >25 1
IV milrinone: Class IIb recommendation specifically if there are signs of left ventricular dysfunction 1. This is crucial because lowering PVR with sildenafil in the setting of LV dysfunction can worsen pulmonary venous hypertension.
ECMO: Class I recommendation for severe PH/hypoxemia refractory to iNO and optimization, especially with OI >40 1
Clinical Decision Framework
If OI >25 on iNO:
- Optimize lung recruitment and ventilation first
- Assess LV function by echo
- If LV dysfunction present → consider milrinone over sildenafil
- If normal LV function → sildenafil is reasonable
- If OI >40 → prepare for ECMO referral regardless of sildenafil use
- If no improvement after 5+ days → evaluate for alveolar capillary dysplasia or other developmental lung disorders 1
Real-World Context
The evidence is equivocal. While guidelines support sildenafil use (Class IIa), the most recent RCT failed to show benefit when added to iNO. However, in resource-limited settings without iNO access, sildenafil appears beneficial for mortality reduction 3.
In practice: IV sildenafil remains a reasonable rescue therapy for severe, iNO-refractory PPHN with OI >25, but clinicians should have realistic expectations about efficacy and maintain close hemodynamic monitoring for hypotension. ECMO should be considered early if OI approaches 40, rather than prolonged trials of multiple vasodilators.